Here's Why HealthEquity (HQY) is a Strong Growth Stock

HealthEquity (HQY) is identified as a strong growth stock by Zacks, despite its #3 (Hold) Zacks Rank, primarily due to its 'A' Growth Style Score and 'B' VGM Score. The company, which provides healthcare account management solutions, is projected to achieve 18.6% year-over-year earnings growth for the current fiscal year, supported by recent upward revisions from four analysts that increased the fiscal 2026 Zacks Consensus Estimate to $3.70 per share. With a historical average earnings surprise of 12.4%, HQY is presented as a compelling consideration for growth-oriented investors.

Analysis

HealthEquity (HQY) presents a dichotomous profile, carrying a neutral Zacks #3 (Hold) rank while exhibiting compelling growth characteristics. The company is forecast to deliver 18.6% year-over-year earnings growth in the current fiscal year, a projection underscored by its top-tier 'A' rating in the Zacks Growth Style Score. Analyst sentiment appears to be improving for the long-term outlook, evidenced by four upward earnings estimate revisions for fiscal 2026 in the past 60 days, which have lifted the consensus estimate to $3.70 per share. Furthermore, HQY has a demonstrated history of outperformance, boasting an average earnings surprise of 12.4%, suggesting a pattern of exceeding market expectations. The company's composite VGM score of 'B' further supports a favorable, albeit not top-ranked, view on its combined value, growth, and momentum attributes.

Key Decisions for Investors

• Growth-oriented investors should consider HQY a candidate for their watchlist, as its projected 18.6% earnings growth and strong analyst revisions present a fundamental case that may outweigh the neutral #3 (Hold) rating.
• Investors should monitor for a potential upgrade in the Zacks Rank, as a shift from 'Hold' to 'Buy' would signal broader alignment with the strong growth metrics and could act as a significant bullish catalyst.
• The consistent track record of delivering an average earnings surprise of 12.4% suggests a pattern of outperformance, which may warrant giving more weight to the company's strong growth outlook than its current neutral rating implies.